Gastrointestinal disorder(s) which, in the opinion of the Qualified/Principal Investigator, would significantly impede the absorption of an oral agent (e.g. intestinal occlusion, active Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection).
Chronic inflammatory bowel disease (Crohn's disease or ulcerative colitis)
History of inflammatory bowel disease (Crohn's or ulcerative colitis)
13. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis);
Presence of a bowel obstruction, history or presence of inflammatory enteropathy, or extensive intestinal resection, Crohn disease, ulcerative colitis, or chronic diarrhea;
Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact drug absorption.
Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).
Active rectal diverticulitis, Crohn's disease affecting the rectum, or ulcerative colitis.
Gastrointestinal disorder(s) which, in the opinion of the Principal Investigator, would significantly impede the absorption of an oral agent (e.g. active Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection).
History of inflammatory bowel disease (e.g., Crohn disease and ulcerative colitis), active bowel inflammation (e.g., diverticulitis)
Active rectal diverticulitis, Crohn's disease affecting the rectum or ulcerative colitis (non-active diverticulitis and Crohn's disease not affecting the rectum are allowed).
History of or active inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
Uncontrolled inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).
Has active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
No preexisting condition that would deter radiotherapy, eg, fistulas, severe ulcerative colitis (particularly participants currently taking sulphasalazine), Crohn's disease, prior adhesions
Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
Any symptomatic autoimmune disease (such as lupus, scleroderma, Crohn's disease, ulcerative colitis) that requires administration of >10mg of prednisone equivalent. Lower dose steroids for conditions such as hypophysitis are allowed.
Uncontrolled inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
Serious intercurrent medical illness which would interfere with the ability of the patient to carry out the treatment program, including, but not limited to, inflammatory bowel disease, Crohn's disease, ulcerative colitis, or active diverticulitis
Prior diagnosis of Crohn's disease or ulcerative colitis
Have gastrointestinal illness or disorder that could affect oral absorption of AP32788 (such as short gut syndrome, Crohn's disease, ulcerative colitis, or CTCAE grade 2 or greater diarrhea of any etiology at baseline).
A documented history of inflammatory bowel disease (ulcerative colitis or Crohn's disease, within three years)
History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).
Active gastrointestinal disease (eg, Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would reasonably impact drug absorption.
Patients with Crohn's disease or ulcerative colitis
Prior diagnosis of Crohn's disease or ulcerative colitis
Active inflammatory disease requiring immunosuppressants, including small or large intestinal inflammation such as Crohn's disease or ulcerative colitis
Subjects who have a history of inflammatory bowel disease, Crohn's disease, ulcerative colitis, or Wegener's granulomatosis;
Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption.
History of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis), celiac disease (ie, sprue), prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect
Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [eg, colitis, Crohn's disease], diverticulitis
Significant gastrointestinal disorder(s) (e.g., active Crohn's disease or ulcerative colitis, or a history of extensive gastric resection and/or small intestinal resection) such that absorption of oral medications is impaired.
Significant gastrointestinal disorder(s) that would, in the opinion of the Principal Investigator, prevent absorption of an orally available agent (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection and small intestinal resection).
History of inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis), celiac disease, prior gastrectomy, gastric bypass, upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption of the study drug and/or predispose the subject to an increased risk of gastrointestinal toxicity.
History of Crohn's Disease or Ulcerative Colitis
Significant gastrointestinal disorder(s) (e.g., active Crohn's disease or ulcerative colitis, or a history of extensive gastric resection and/or small intestinal resection) such that absorption of oral medications is impaired.
Uncontrolled inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
Inflammatory bowel disease including Crohn's disease and colitis ulcerosa.
Have a bowel obstruction, history or presence of inflammatory enteropathy or extensive intestinal resection (hemicolectomy or extensive small intestine resection with chronic diarrhea), Crohn's disease, ulcerative colitis, or chronic diarrhea.
Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)
Medical history of autoimmune disease (e.g., Crohn's disease, ulcerative colitis) or other diseases requiring systemic glucocorticoid or immunosuppressive therapy.
Recent or ongoing clinically significant GI disorder, e.g. Crohn's Disease, Ulcerative Colitis, or prior total or partial gastrectomy.
Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)
Uncontrolled inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
Significant gastrointestinal disorder(s), in the opinion of the Principal Investigator, (e.g., Crohn's disease, ulcerative colitis, extensive gastric resection and small intestinal resection)
Significant gastrointestinal disorder(s), in the opinion of the Principal Investigator, (e.g., Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection)
Have a history of inflammatory bowel disease (Crohn's disease or ulcerative colitis)
Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
Diagnosis of inflammatory bowel disease (Crohn's disease or Ulcerative Colitis).
Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
Active inflammatory bowel disease (i.e., Crohn's disease or ulcerative colitis)
Active peptic ulcer disease, inflammatory bowel disease (eg, ulcerative colitis, Crohn's disease), diverticulitis, or other gastrointestinal conditions with increased risk of perforation or gastrointestinal bleeding.
History of prior or currently active small or large intestine inflammation (such as Crohn's disease or ulcerative colitis). Any predisposition for gastrointestinal (GI) toxicity requires prior approval from the Medical Monitor.
Inflammatory bowel disease including Crohn's disease and colitis ulcerosa.
Significant gastrointestinal disorder(s), (e.g., Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection) such that, in the opinion of the treating investigator, absorption of oral medications may be impaired.
Participants with active gastrointestinal conditions (Crohn's disease, ulcerative colitis, diverticulosis associated colitis, and Behçet's disease)
Active small or large intestine inflammation (such as Crohn's disease or ulcerative colitis)
Patient with Crohn's colitis or ulcerative colitis
Previous medical history of gastrointestinal obstruction or perforation, toxic megacolon, major colonic resection, severe diverticulitis, heart failure (Class III or IV), serious cardiovascular disease, ulcerative colitis or Crohn's disease.
Significant gastrointestinal disorder(s), in the opinion of the Principal Investigator, (e.g., Crohn's disease, ulcerative colitis, extensive gastric and small intestine resection)
Inflammatory bowel disease, active rectal diverticulitis, Crohn's disease affecting the rectum, anal stenosis or ulcerative colitis. (Nonactive diverticulitis and Crohn's disease not affecting the rectum are allowed)